Navigation Links
ANP to present at and attend major US investment, partnering and industry conferences
Date:8/28/2013

USA Investor/Media: Joshua Drumm 212-375-2664; jdrumm@tiberend.com

Australia Investor/Media: Simon Watkin +61 413 153272; simon@marketconnect.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.


'/>"/>
SOURCE Antisense Therapeutics Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cambridge Semantics to Present on ‘Smart Data’ During Deep-Dive Workshop at 2013 Big Data Innovation Summit
2. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
3. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
4. AbbVie to Present at Morgan Stanley Global Healthcare Conference
5. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
6. iLab Solutions to Present SRA International Webinar for Research Administrators
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
8. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
9. GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
10. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
11. Novus International to Present Scientific Findings on Prebiotics during Aquaculture Europe 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... When a downtown ... response was swift and efficient thanks to the continuing efforts of members of ... of more than 50 stakeholders, including officials from area counties and cities, Renewable ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... that it has appointed Vishwas Paralkar to the role of chief scientific officer. ... technology. He will report to Cybrexa’s president and CEO, Per Hellsund. , “I ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... examining the effects of exoskeleton-assisted walking on gait parameters and neuromuscular activity ... "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) was ...
(Date:9/19/2017)... ... September 19, 2017 , ... The latest ... dangerous step of sample prep for metals digestion—the addition of acids and reagents. ... affordable price. The system is ideal for any laboratory performing their own unique ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):